These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 10674266)
41. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Goutas N; Vlachodimitropoulos D; Bouka M; Lazaris AC; Nasioulas G; Gazouli M Anticancer Res; 2008; 28(1A):305-8. PubMed ID: 18383861 [TBL] [Abstract][Full Text] [Related]
42. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Elisei R; Shiohara M; Koeffler HP; Fagin JA Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724 [TBL] [Abstract][Full Text] [Related]
43. [Advances in poorly differentiated thyroid carcinoma]. Sun J; Yang D; Cui QC Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):850-3. PubMed ID: 22336216 [No Abstract] [Full Text] [Related]
44. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Wright PA; Williams ED; Lemoine NR; Wynford-Thomas D Oncogene; 1991 Mar; 6(3):471-3. PubMed ID: 2011403 [TBL] [Abstract][Full Text] [Related]
46. The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730 [TBL] [Abstract][Full Text] [Related]
47. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273 [TBL] [Abstract][Full Text] [Related]
48. Detection of activated ras oncogenes in human thyroid carcinomas. Suárez HG; Du Villard JA; Caillou B; Schlumberger M; Tubiana M; Parmentier C; Monier R Oncogene; 1988 Apr; 2(4):403-6. PubMed ID: 3283656 [TBL] [Abstract][Full Text] [Related]
49. [Molecular basis of tumors arising in thyroid follicular cells]. Wynford-Thomas D Ann Chir; 1999; 53(3):237-43. PubMed ID: 10339867 [TBL] [Abstract][Full Text] [Related]
50. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240 [TBL] [Abstract][Full Text] [Related]
51. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992 [TBL] [Abstract][Full Text] [Related]
52. Ras oncogene mutations in benign and malignant thyroid neoplasms. Karga H; Lee JK; Vickery AL; Thor A; Gaz RD; Jameson JL J Clin Endocrinol Metab; 1991 Oct; 73(4):832-6. PubMed ID: 1890154 [TBL] [Abstract][Full Text] [Related]
53. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Nikiforov YE Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856 [TBL] [Abstract][Full Text] [Related]
54. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Hara H; Fulton N; Yashiro T; Ito K; DeGroot LJ; Kaplan EL Surgery; 1994 Dec; 116(6):1010-6. PubMed ID: 7985080 [TBL] [Abstract][Full Text] [Related]
55. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Namba H; Rubin SA; Fagin JA Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998 [TBL] [Abstract][Full Text] [Related]
56. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975 [TBL] [Abstract][Full Text] [Related]
57. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375 [TBL] [Abstract][Full Text] [Related]
58. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival. Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797 [TBL] [Abstract][Full Text] [Related]
59. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309 [TBL] [Abstract][Full Text] [Related]
60. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]